Back to search

Article

DPYD (Dihydropyrimidine Dehydrogenase) Variant c.2194G>A (Normal Metabolizer) with Severe Toxicities in Patients Treated with Fluoropyrimidine Based Regimens. A first Case Report from Bihar, India

2024-09-26

Abstract excerpt

<title>Abstract</title> <p>The first-line medications used in clinics for colorectal cancer (CRC) are 5-FU based chemotherapy and its prodrug, capecitabine. Nevertheless, there are still relatively few patients responding to 5-FU/capecitabine-based therapy. Up to 30% of patients treated with 5-FU experience early-onset severe toxicity, including diarrhea, nausea, mucositis, stomatitis, myelosuppression, neurotoxi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5ca59004-a616-5069-a974-01ac94eda70b
DOI
10.21203/rs.3.rs-5025385/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
DPYD (Dihydropyrimidine Dehydrogenase) Variant c.2194G&gt;A (Normal Metabolizer) with Severe Toxicities in Patients Treated with Fluoropyrimidine Based Regimens. A first Case Report from Bihar, IndiaDOI 10.21203/rs.3.rs-5025385/v1
Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.Semantic proximity
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patientsSemantic proximity
Tailored treatment and clinical management for DPYD compound heterozygous: a multidisciplinary teamworkSemantic proximity
Opportunistic analysis of clinically actionable DPYD gene variants in a germline testing cohort in India.Semantic proximity
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].Semantic proximity
The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control studySemantic proximity
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.Semantic proximity
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.Semantic proximity
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.Semantic proximity
Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphismsSemantic proximity
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.Semantic proximity
Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.Semantic proximity
Select a neighboring publication to make it the new centre.